Three patients developed veno-occlusive disease of the liver (VOD) after allogeneic stem cell transplantation. On the day after diagnosis, N-acetylcysteine (NAC) was given, initially in loading doses and thereafter 50-150 mg/kg/day for 12 to 31 days. The maximum bilirubin levels were 137, 58 and 138 mmol/l in the three patients, respectively. After the introduction of NAC, bilirubin, aspertate aminotransferase, sIL-2 receptor and IL-8 decreased. All three patients achieved normal bilirubin levels and prothrombin times. To conclude, NAC may be useful for treatment of VOD. Bone Marrow Transplantation (2000) 25, 993-996.
The incidence has been reported to be between 10 and 70% with a mortality rate of 30-50%, depending on clinical criteria for diagnosis and severity. Chemotherapy and/or irradiation causes endothelial injury, which is the initiating factor for the pathological process of VOD. Pathologically, VOD is due to progressive and concentric narrowing or fibrous obliteration of terminal hepatic venules and small lobular veins. This leads to necrosis of hepatocytes in the central lobular areas which results in portal hypertension and hepatic failure. Cytokines are also involved. TNF-␣ may play a role as a mediator of endothelial cell damage. 3 Furthermore, soluble IL-2 receptors (sIL-2R) and IL-8 are also increased during VOD. 4, 5 N-acetylcysteine (NAC) is a thiol anti-oxidant used as a mucolytic agent and as an antidote for an overdose of paracetamol. 6 NAC may block the activation of some protein kinases and may reduce cell death mediated by oxidative stress. 7 We report here our successful experience with NAC given to three patients with VOD after ASCT. 
Case reports
A 44-year-old male with high-grade non-Hodgkin's lymphoma (UPN 684) received peripheral stem cells (8 × 10 8 mononuclear cells/kg containing 3.6 × 10 6 CD34 + cells/kg) from his HLA-identical brother, after conditioning with cyclophosphamide (120 mg/kg) and 10 Gy of total body irradiation. Cyclosporine combined with four doses of methotrexate was given as immunosuppression. A detailed description of the myeloablative therapy, immunosuppression and patient care has been published elsewhere. 8 On day 14 after ASCT, his bilirubin increased to 45 mol/l. He gained 9 kg (14%) in weight and developed painful hepatomegaly. Duplex sonography on day 14 indicated a thickened gall-bladder, decreased blood flow in the portal vein (1 dm/s), thin liver veins with continuous pathological flow and ascites. Treatment with alteplase (Actilyse 10 mg/day i.v., Boehringer Ingelheim, Ingelheim, Germany) was given on 4 consecutive days ( Figure 1 ). On day 15, NAC was started (150 mg/kg i.v. for 15 min followed by 50 mg/kg for 4 h and thereafter 150 mg/kg daily for 24 days). Vitamin K 10 mg ϫ 1 i.v., heparin 8000 IE/day, spironolactone, lactulose and metronidazole were also given because of liver failure. Maximum levels of alanine aminotransferase (ALT) were reached (26 kat/l) on day 18, of aspartate aminotransferase (AST) (60 kat/l) on day 17 and of bilirubin (137 mol/l) on day 20 (Figure 1 ). The prothrombin time (PT) was 2.9, according to the international normalized ratio (INR), on day 17. TNF-␣ increased to 5.9 pg/ml (normal Ͻ4). IL-8 increased from Ͻ10 pg/ml to a maximum of 671 on day 16 (Figure 1 ). sIL-2R in serum increased from 454 pg/ml to a peak of 8018 pg/ml on day 16. Drainage of between 2 and 4 l of ascites was performed on seven occasions because of abdominal distension with a maximum weight increase of 20 kg. Pleural fluid causing dyspnoea was removed twice (1.9l and 0.7 l, respectively). As a result of hepatic insufficiency, the patient was confused, somnolent and had flapping tremor for several weeks. EEG showed metabolic encephalopathy. However, he gradually improved and was taken off NAC on day 38. He was discharged 2. months after ASCT with a bilirubin of 36 mol/l, ALT of 0.12 kat/l, AST of 0.44 kat/l and a normal PT of INR 1.15. The values remain normal and he is now well at home 9 months after ASCT.
The second patient, an 8-year-old girl with AML M4 in second remission (UPN 693), received bone marrow Arrows indicate administration of 10 mg of Actilyse. *Drainage of ascites. BILI = bilirubin, mol/l; AST = aspartate aminotransferase, kat/l; ALT = alanine aminotransferase, kat/l; cytokines: sIL-2R = soluble interleukin-2 receptor, pg/ml; interleukin-6 and 8, pg/ml. Normal levels are indicated by horizontal dotted lines. Normal levels: bilirubin Ͻ26 mol/l, IL-2R 676-2132 pg/ml, IL-6 Ͻ12 pg/ml, IL-8 30 pg/ml.
(1 ϫ 10 8 mononuclear cells/kg) from an unrelated donor after conditioning with busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg). Before the transplant, she was given thymoglobuline (IMTIX Sangstat, Lyons, France) 2 mg/kg/day on day −2 to day −1.
8 Prophylaxis against GVHD consisted of cyclosporine and methotrexate. On day 18, the bilirubin level rose to 55 mol/l. She gained 3 kg (12%) in weight and had pain below her right costal margin. Duplex sonography showed hepatosplenomegaly, ascites, a right-sided pleural exudate and a thickened gallbladder. The liver veins were patent, but narrow. She was given one dose of alteplase 5 mg i.v., which was discontinued after a major nosebleed. Her Hb decreased from 77 g/l to 58 g/l. NAC was given from day 19 in the same dose as to the preceding patient and continued at 100 mg/kg/day for 11 days, reduced to 50 mg/kg/day for 2 days and discontinued on day 31. She was also given vitamin K 5 mg ϫ 1 i.v., spironolactone and heparin 2500 IE/day. Bilirubin reached a maximum level of 58 mol/l on day 23 ( Figure  2 ). TNF-␣ was 6.6 pg/ml. After NAC was given, TNF-␣ and sIL-2R decreased. The INR value for PT increased from 1.36 pretransplant to 2.00. The ALT and AST levels remained normal. She gradually improved and was discharged on day 33, with a bilirubin level of 17 mol/l and a normal PT of 1.21. She is well at home 8 months after ASCT. He developed VOD on day +10 with extensive pain below the right costal margin, a bilirubin level of 41 mol/l and a weight gain of 5 kg (10%) (Figure 3 ). Duplex sonography showed pathological flows in the liver veins and later a thickened gall-bladder wall. NAC was given from the day of diagnosis (100 mg/kg/day) for 31 days. From day +11, he was given Actilyse 10 mg/day i.v. for 4 consecutive days. Bilirubin reached a maximum of 138 mol/l on day +16 and PT 2.0. Bilirubin was 16 mol/l and PT 1.01 48 days after ASCT. TNF-␣ was 6.9 pg/ml already on day +2, IL-8 had a maximum on day +2 of 1179 pg/ml and IL-2R had a peak on day +18 with 11691 pg/ml. Cytokine levels normalised. In addition to his VOD, he had bronchopneumonia and was treated in the ICU. He had diarrhoea because of Clostridium difficile and acute GVHD of the skin on day +19 and of the liver on day +31, which responded to steroids. He is now at home and well 4 months after ASCT.
Discussion
All three patients fulfilled the VOD diagnostic criteria stated by Jones and co-workers: 2 an onset before day 21 of hyperbilirubinaemia and at least two of three other findings: tender hepatomegaly, unexpected weight gain Ͼ5% and ascites. Furthermore, TNF-␣ and sIL-2R in serum was increased in all patients at diagnosis. TNF-␣ release may be an initiating factor or may be part of a cascade of immunological events. 3 Release of IL-8 and sIL-2R provides evidence of immune activation during VOD. IL-8 is produced by macrophages, endothelial cells and hepatocytes and plays a major role in the modulation of inflammatory responses. We have found that monitoring of the IL-8 and sIL-2R levels is useful for diagnosing and determining the prognosis of VOD. 4, 5 After treatment with NAC was given, inflammatory cytokines seemed to be shut off (Figures 1-3) . sIL-2R decreased in all three patients. IL-8 was only moderately increased in patients 1 and 3, with peak values of 671 and 1180 pg/ml, and remained low in the second patient. This is in contrast to our previous experience with a median peak level of 5546 ng/ml in 11 patients with VOD, who were not treated with NAC. 5 Once VOD is diagnosed, there is no proven specific therapy, and the case-fatality rate may reach 50%.
1 Alteplase has been tried with some success, but may result in severe haemorrhages as seen in patient 2. 9 In our experience, alteplase treatment has not by far resulted in such a dramatic effect on liver parameters as was seen in these three patients treated with NAC. 9, 10 Heparin was given only to patient No. 1. However, in our experience, heparin 100 IU/h given as continuous infusion during the first month had no effect on the frequency of VOD. 11 In patients with VOD and deteriorating liver function, liver transplantation may be an option. However, in our experience, three patients who underwent liver transplantation died of complications. 9, 10 The encouraging outcome in these three patients suggests that NAC may be a therapeutic option. These are three anecdotal cases and to prove the efficacy of NAC, a wellBone Marrow Transplantation controlled prospective randomised study should be performed. Still, we want to speculate that NAC inhibits the effects of free radicals and oxidative stress during VOD. NAC is a thiol that reacts with reactive oxidative intermediates and replenishes the intracellular cysteine necessary for the production of glutathione, an endogenous antioxidant.
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NAC has been used as a mucolytic agent in various pulmonary disorders and as an antidote for acetaminophen overdose. Recent studies show that NAC suppresses proliferation of NIH 3T3 fibroblast cells, and this antiproliferative effect is mediated by reversible blocking cell-cycle progression in G1 phase. 12 By blocking some protein kinases, NAC may reduce cell death mediated by oxidative stress during VOD. 7 The first patient had severe VOD, which in our experience has led to liver failure and death in most patients. In patients 1 and 3, we have a strong feeling that NAC reversed an otherwise dismal outcome. The 8-year-old girl had much milder VOD and would probably have recovered from this disease even without NAC. However, her recovery was much faster than expected.
Since we stopped using norethisterone to prevent menstrual haemorrhages during the thrombocytopenic phase after ASCT, the incidence of VOD has decreased among our patients. 13 This policy did not affect these three patients. However, as the prognosis of liver VOD is usually very poor, we now plan to do a randomized prospective prophylaxis trial in patients with high-risk criteria for VOD.
To conclude, NAC gave encouraging results in three patients with VOD. While awaiting the results to prove its efficacy, NAC may be tried, because it is cheap and there are almost no side-effects.
